Lys Therapeutics is developing LYS241, a fully humanized, Fc‑silent IgG1 monoclonal antibody designed to selectively block the pathological interaction between tissue plasminogen activator (tPA) and NMDA receptors while preserving physiological receptor function. The company is positioning LYS241 to address blood‑brain barrier dysfunction, neuroinflammation and excitotoxicity across Parkinson’s disease, synucleinopathies including multiple system atrophy, and ischemic stroke. Preclinical data cited by the company support potential effects on BBB dysfunction, neuroinflammation and neurodegenerative progression, and suggest relevance as a standalone or adjunctive therapy in ischemic stroke to improve reperfusion quality and reduce complications. Lys has completed preclinical, regulatory, manufacturing and translational milestones and plans a biomarker‑rich Phase 1a/1b program including healthy volunteers and indication‑specific patient cohorts. Financially, the company has raised more than €25 million since founding in 2021, including a grant of over $5 million from The Michael J. Fox Foundation and support from Bpifrance, France 2030 and private investors.

Total raised

$34M

Funding rounds

3

Latest round

Grant

Latest activity

Jun 2026